Direkt zum Inhalt
Merck

Evaluation of 9-cis-retinyl acetate therapy in Rpe65-/- mice.

Investigative ophthalmology & visual science (2009-05-02)
Tadao Maeda, Akiko Maeda, Gemma Casadesus, Krzysztof Palczewski, Philippe Margaron
ZUSAMMENFASSUNG

Mice lacking retinal pigment epithelium-specific 65-kDa protein (RPE65) develop retinopathy and blindness resembling Leber congenital amaurosis. Effects of 9-cis-retinyl acetate (9-cis-R-Ac) on visual function and retinopathy progression were tested in Rpe65(-/-) mice. Young C57Bl/6 mice were given 9-cis-R-Ac in each of four different oil-based vehicle solutions by gastric gavage to identify the vehicle most suitable for drug delivery by measuring retinoid levels in plasma. Then doses of 9-cis-R-Ac ranging from 1 to 100 mg/kg were administered to 5- to 12-week-old Rpe65(-/-) mice by different treatment regimens, including single doses and either intermittent or daily doses for various periods up to 8 weeks. Retinoid effects on visual function were evaluated by electroretinography, retinoid analyses, histologic methods, and vision-dependent behavioral testing. Soybean oil vehicle provided the highest 9-cis-R-Ac metabolite levels in plasma. Single doses of 9-cis-R-Ac (6.25-50 mg/kg) provided significant dose-dependent improvement in electroretinographic responses. Well-tolerated daily doses (1-12.5 mg/kg) for 2 weeks induced remarkable improvement of retinal function. Significant dose-dependent improvement of electroretinographic responses was observed 6 days after administration of 9-cis-R-Ac daily for 3 days at 1 to 12.5 mg/kg. Mice given either daily or intermittent 9-cis-R-Ac treatment at 1 and 4 mg/kg and evaluated 8 weeks later displayed dose-dependent improvement of retinal function and morphology, whereas retinal function deteriorated in control animals. Treated mice also performed better than control animals in vision-dependent behavioral tests. Treatment with 9-cis-R-Ac improves visual function and preserves retinal morphology in Rpe65(-/-) mice.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Supelco
Retinylacetat (Vitamin-A-Acetat), Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Retinylacetat, synthetic, crystalline solid or supercooled liquid
Supelco
Retinylacetat, analytical standard
Sigma-Aldrich
Retinylacetat, BioReagent, solid or viscous liquid, synthetic, suitable for cell culture
Sigma-Aldrich
Retinylacetat, synthetic, matrix dispersion, 475,000-650,000 USP units/g
Retinolacetat, European Pharmacopoeia (EP) Reference Standard